Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) saw its stock price increase by over 13% in early trading, currently up 8.94% at HKD 13.52, with a trading volume of HKD 40.7033 million [1] Group 1 - The company announced that its investigational first-class new drug, Tazemetostat (TY-9591), has been included in the priority review list by the National Medical Products Administration (NMPA) [1] - Tazemetostat is intended for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 substitutions, along with central nervous system metastases [1] - The inclusion in the priority review list signifies an acceleration in the review process for Tazemetostat, potentially leading to an earlier market launch and providing new treatment options for patients in China [1]
港股异动 | 同源康医药-B(02410)早盘涨超13% 甲磺酸艾多替尼片获纳入优先审评品种名单